Bausch Health Companies Inc. - SIC # 2840 -

Ticker Exchange SIC # Website Latest Ticker
BHC New York 2840 www.bauschhealth.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Bausch Health Companies Inc.

Bausch Health CEO Thomas J. Appio Joins Bausch + Lomb Board - Aug 6th, 2026 5:04 am
Bausch + Lomb Announces Board of Directors Update, Reaffirms Guidance - Aug 6th, 2026 5:00 am
Bausch Health (BHC) Rockets 28% as Q2 Turnaround Fuels Recovery Outlook - Jul 30th, 2026 10:03 pm
Sector Update: Healthcare Stocks Decline Late Afternoon - Jul 30th, 2026 1:46 pm
BHC Q2 Earnings Beat Estimates on Salix and Solta Growth, '26 View Raised - Jul 30th, 2026 10:33 am
Bausch Health Companies Inc. Q2 2026 Earnings Call Summary - Jul 30th, 2026 6:30 am
Bausch Health Cos Q2 Earnings Call Highlights - Jul 29th, 2026 7:04 pm
Bausch Health (BHC) Q2 Earnings and Revenues Beat Estimates - Jul 29th, 2026 6:35 pm
Bausch (BHC) Reports Q2 Earnings: What Key Metrics Have to Say - Jul 29th, 2026 5:30 pm
BAUSCH HEALTH ANNOUNCES SECOND QUARTER 2026 RESULTS, RAISES GUIDANCE - Jul 29th, 2026 2:05 pm
(Pr)ELIDEL® (pimecrolimus) cream Now Reimbursed Under Alberta's Public Drug Plan for Eligible Patients with Mild to Moderate Atopic Dermatitis - Jul 28th, 2026 6:00 am
Bausch Health’s (BHC) Canadian Subsidiary Lists PrOKEDI Dosages in RAMQ Formulary - Jul 12th, 2026 11:21 am
Bausch Health to Announce Second Quarter 2026 Results on July 29, 2026 - Jul 7th, 2026 5:00 am
Québec is the first province to list (Pr)OKEDI(MC) (extended-release injectable suspension of risperidone) on the public drug reimbursement formulary for the treatment of schizophrenia - Jul 6th, 2026 5:00 am
Michael Goettler Resigns from Bausch Health's Board of Directors - Jul 1st, 2026 2:15 pm
Bausch Health, Canada Inc. and the pan-Canadian Pharmaceutical Alliance sign letter of intent for public drug plan coverage of (Pr)OKEDI® (Risperidone for extended-release injectable suspension) for the treatment of schizophrenia - Jun 9th, 2026 6:00 am
Bausch (BHC) Down 5.4% Since Last Earnings Report: Can It Rebound? - May 29th, 2026 9:30 am
Bausch Health's Aesthetic Business, Solta Medical, Earns Prestigious Trademark Certification of Thermage® in China - May 28th, 2026 2:15 pm
Oligometastatic Disease Market Analysis Report 2026-2036, Profiles of Leading Players - Dompe Farmaceutici, Bausch Health, Merck, Pfizer, and Glenmark Pharmaceuticals - May 21st, 2026 7:02 am
Bausch Health Announces 2026 Annual Meeting of Shareholder Results - May 19th, 2026 2:15 pm